Bertolini F - Search Results

1

The multifaceted circulating endothelial cell in cancer: towards marker and target identification.

Bertolini F, Shaked Y, Mancuso P, Kerbel RS. Bertolini F, et al. Nat Rev Cancer. 2006 Nov;6(11):835-45. doi: 10.1038/nrc1971. Epub 2006 Oct 5. Nat Rev Cancer. 2006. PMID: 17036040 Review.

2

Systemic effects of surgery: quantitative analysis of circulating basic fibroblast growth factor (bFGF), Vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF-beta) in patients with breast cancer who underwent limited or extended surgery.

Curigliano G, Petit JY, Bertolini F, Colleoni M, Peruzzotti G, de Braud F, Gandini S, Giraldo A, Martella S, Orlando L, Munzone E, Pietri E, Luini A, Goldhirsch A. Curigliano G, et al. Among authors: bertolini f. Breast Cancer Res Treat. 2005 Sep;93(1):35-40. doi: 10.1007/s10549-005-3381-1. Breast Cancer Res Treat. 2005. PMID: 16184456

3

Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma.

Monestiroli S, Mancuso P, Burlini A, Pruneri G, Dell'Agnola C, Gobbi A, Martinelli G, Bertolini F. Monestiroli S, et al. Among authors: bertolini f. Cancer Res. 2001 Jun 1;61(11):4341-4. Cancer Res. 2001. PMID: 11389057

4

The circulating endothelial cell in cancer: towards marker and target identification.

Martin-Padura I, Bertolini F. Martin-Padura I, et al. Among authors: bertolini f. Curr Pharm Des. 2008;14(36):3780-9. doi: 10.2174/138161208786898635. Curr Pharm Des. 2008. PMID: 19128231 Review.

5

Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers.

Bertolini F, Mingrone W, Alietti A, Ferrucci PF, Cocorocchio E, Peccatori F, Cinieri S, Mancuso P, Corsini C, Burlini A, Zucca E, Martinelli G. Bertolini F, et al. Ann Oncol. 2001 Jul;12(7):987-90. doi: 10.1023/a:1011141009812. Ann Oncol. 2001. PMID: 11521807

6

Inhibition of angiogenesis and induction of endothelial and tumor cell apoptosis by green tea in animal models of human high-grade non-Hodgkin's lymphoma.

Bertolini F, Fusetti L, Rabascio C, Cinieri S, Martinelli G, Pruneri G. Bertolini F, et al. Leukemia. 2000 Aug;14(8):1477-82. doi: 10.1038/sj.leu.2401854. Leukemia. 2000. PMID: 10942245

7

Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma.

Bertolini F, Fusetti L, Mancuso P, Gobbi A, Corsini C, Ferrucci PF, Martinelli G, Pruneri G. Bertolini F, et al. Blood. 2000 Jul 1;96(1):282-7. Blood. 2000. PMID: 10891463

8

Human myeloid and lymphoid malignancies in the non-obese diabetic/severe combined immunodeficiency mouse model: frequency of apoptotic cells in solid tumors and efficiency and speed of engraftment correlate with vascular endothelial growth factor production.

Fusetti L, Pruneri G, Gobbi A, Rabascio C, Carboni N, Peccatori F, Martinelli G, Bertolini F. Fusetti L, et al. Among authors: bertolini f. Cancer Res. 2000 May 1;60(9):2527-34. Cancer Res. 2000. PMID: 10811135

9

Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma.

Bertolini F, Paolucci M, Peccatori F, Cinieri S, Agazzi A, Ferrucci PF, Cocorocchio E, Goldhirsch A, Martinelli G. Bertolini F, et al. Br J Haematol. 1999 Aug;106(2):504-9. doi: 10.1046/j.1365-2141.1999.01547.x. Br J Haematol. 1999. PMID: 10460612

10

Angiogenesis in myelodysplastic syndromes.

Pruneri G, Bertolini F, Soligo D, Carboni N, Cortelezzi A, Ferrucci PF, Buffa R, Lambertenghi-Deliliers G, Pezzella F. Pruneri G, et al. Among authors: bertolini f. Br J Cancer. 1999 Dec;81(8):1398-401. doi: 10.1038/sj.bjc.6693515. Br J Cancer. 1999. PMID: 10604739 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results